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Several lines of evidence suggest that cellular immunity plays an important 
role in the defense against herpes simplex virus (HSV)  l infections.  First,  HSV 
can persist both in vivo and in vitro despite the presence of high concentrations 
of neutralizing antibody (1). Second, HSV infections are more severe in patients 
with deficiencies in cellular immunity (2-4). Third, experimental suppression of 
the cellular immune response makes animals more susceptible to HSV infection 
(2, 4). The precise way by which cell-mediated immunity operates to protect the 
host  against HSV is far from clear; but  recent  studies  suggest  that  different 
immunological  mechanisms  are  required  to  control  different  modes  of  viral 
spread (5). For example, in the typical lytic infection, HSV can spread by either 
the extracellular route (Type I  spread) or directly from cell-to-contiguous-cell 
(Type II spread) presumably as a result of cell fusion. Type I  spread is readily 
stopped  by  antiviral  antibody  that  neutralizes  extraceUular  virus.  Type  II 
spread is not stopped by antiviral  antibody because the intracellular location 
of the virus protects it from neutralization. 
Little is still known about how the host combats Type II spread, but theoretically, 
the immune response  could  stop Type II spread by acting on one or more of three 
different  sites.  First, it could  act by destroying virus-infected  cells. Second,  it could 
break cell-to-cell contact or prevent cell fusion; if this happens the virus would have to 
travel by the extracellular route to infect adjacent cells and the virus could  then be 
neutralized by antiviral antibody. Third, if the host's immune response  leads to the 
destruction of the surrounding uninfected  cells or inhibits viral replication  in  these 
cells, the spread of virus would be halted. 
Evidence that the immune response of the host can directly or indirectly act at each 
of these sites is beginning to accumulate. It is known that HSV can induce new antigens 
on the surface of infected  cells and that antiviral antibody and complement can react 
I A bbrevlations used in this paper: C  FA, complete Freund's adjuvant; GM, growth medium; 
HSV, herpes simplex virus; IFA, incomplete Freund's adjuvant;  MEM, minimum essential 
medium; PBS, phosphate-buffered  saline; PEC, peritoneal exudate cells; PFU, plaque-forming 
units; PPD, purified protein derivative; RK, rabbit kidney; VSV, vesicular stomatitis virus. 
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with these antigens and destroy the infected cell (6). The critical question, however, is 
not whether the infected cell is immunologically destroyed, but whether the destruc- 
tion occurs before the virus is transmitted to contiguous infected cells. If the infected 
cell is immunologically destroyed after the virus is transmitted to contiguous unin- 
fected cells, the infection would not be stopped. Recent in vitro studies suggest that 
this latter situation is what occurs in HSV infections (7). The failure to halt the spread 
of HSV by an immunological attack directed specifically  at infected cells suggested 
that  factors which could disrupt the  connection between contiguous cells  or could 
inhibit viral replication in adjacent cells might be needed to stop viral spread. Support 
for this contention comes from experiments which showed  that when peritoneal exu- 
date leukocytes, obtained from animals that had never been exposed  to HSV, were 
added to monolayers of cells infected with HSV, the spread of the virus was inhibited 
(7). High concentrations of viable leukocytes were required, and they appeared to act 
by exerting a  toxic effect  on the  underlying monolayer. This disrupted cell-to-cell 
contact and thereby allowed  antiviral antibody and complement to destroy infected 
cells before cell-to-cell  contact was reestablished. Supernatant fluids from these cul- 
tures did not inhibit the formation of HSV plaques nor contain measurable amounts of 
interferon. It was concluded that the leukocytes acted primarily by preventing cell-to- 
cell contact and thereby converting a Type II into a Type I spread. 
The present experiments were initiated to see (a)  whether leukocytes sensi- 
tized and stimulated by a specific antigen were more effective than unsensitized 
leukocytes in inhibiting viral  replication and  (b)  whether  soluble mediators 
released from sensitized and stimulated leukocytes could inhibit viral replica- 
tion by acting on uninfected cells. 
Materials and Methods 
Tissue Culture and Media.--Rabbit kidney (RK) cells were prepared as previously described 
(8). Growth medium  (GM) consisted of Eagle's  minimum essential medium  (MEM)  with 
L-glutamine, 10% heat-inactivated  fetal calf serum and antibiotics  (100 U of penicillin-G/ml 
and 1.0/Jg of fungizone/ml). After the RK cells had grown to confluency, they were removed 
by trypsinization,  washed, resuspended in MEM  with  20% calf serum and 10% dimethyl 
sulfoxide, and stored in liquid nitrogen. From this stock cell preparation,  third  and fourth 
passage RK monolayers were prepared and used. Dulbecco's phosphate-buffered saline (PBS) 
with Ca  ++ and Mg  ++ was used to wash monolayers. 
Viruses.--HSV (type 1) was prepared and assayed in RK cells (8). To prevent development 
of secondary plaques, 2% pooled human serum containing antibody to HSV-I was added to 
the growth medium (antibody overlay medium). Vesicular stomatitis  virus (VSV), (Indiana 
strain), obtained from the American Type Cell Culture Collection, Rockville, Md. was grown 
and assayed in RK cells. 
Antigens.--Tuberculin-purified  protein derivative (PPD) was obtained from Parke, Davis 
and Co., Detroit, Mich. 100 ml of HSV-1, containing 1 >( 108 plaque-forming units (PFU)/ml, 
were centrifuged at 81,000 g for 1 h. The virus pellet was suspended in 20 ml PBS, sonicated, 
and exposed for 10 min at 15 cm to two 15-watt germicidal lamps (General Electric Co., Seh- 
nectady,  N.Y.). The UV-inactivated virus then was recentrifuged at 81,000 g for 1 h, sus- 
pended in 10 ml GM, sonicated, and stored at --70°C until used. All UV-inactivated  HSV 
preparations were tested and found to be free of infectious virus. 
Sensitization of Leukocytes.--New Zealand white rabbits, weighing 2-3 kg, were immunized 
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terium tuberculosis (strain Jamaica); each animal received 1 ml divided between the hind foot- 
pads and  back  of the neck.  Rabbits immunized subcutaneously with incomplete Freund's 
adjuvant (IFA) served as controls. Skin tests were performed 1 wk before harvest of leukocytes 
with 5/~g of PPD. A test was considered positive if the redness and induration exceeded 20 )< 
20 mm at 48 h. Splenic leukocytes or peritoneal exudate cells (PEC) were harvested 3-6 mo 
after immunization. 
Rabbits were immunized against HSV by intravenous inoculation of 3 ×  l0  s PFU of infec- 
tious virus. Splenic leukocytes or PEC were harvested 9-12 days after immunization (9). Skin 
tests were not performed on HSV-inoculated rabbits. 
Harvest of Sensitized  Leukocytes.--Rabbit PEC were collected 3 days after the intraperi- 
toneal injection of 50 ml of sterile 12.5% sodium caseinate (7). Approximately 70-80% of the 
PEC from both M. tuberculosis- and HSV-sensitized rabbits were macrophages or monocytes; 
the remainder were polymorphonuclear leukocytes and small lymphocytes. More than 92% of 
the cells were viable as measured by exclusion  of trypan blue.  Except where indicated other- 
wise, PEC will be referred to hereafter as sensitized leukocytes. 
Spleens were obtained aseptically, trimmed of excess adipose tissue, minced with scissors, 
and suspended in GM by gently forcing the mince through a stainless steel screen. The  sus- 
pended cells then were filtered through a double layer of sterile gauze and centrifuged at 800 g 
for 5 min. The pellet was exposed to 15 ml of 0.2% NaCI for 30 sec to lyse erythrocytes. Im- 
mediately thereafter, 15 ml of 1.6% NaCI was added; the cells then were centrifuged and re- 
suspended in either GM or antibody overlay media. 80-85% of the spleen cells were viable as 
measured by exclusion of trypan blue. 
Incubation of Sensitized Leukocytes with HSV-Infected  Monolayers.--Confluent  monolayers 
of RK cells in trays (Linbro Chemical Co., Inc., New Haven, Conn.) containing 24 wells  (16 
mm in diameter) were washed once with PBS and incubated at 37°C with approximately 30 
PFU of HSV suspended in 0.2 ml of GM. At the end of 2 h the inocula were aspirated and the 
monolayers washed. Either CFA-sensitized leukocytes plus PPD in 2 ml of antibody overlay 
medium or HSV-sensitized  leukocytes plus UV-inactivated HSV in 2 ml of GM (without anti- 
body) were added to each well. In most instances, the leukocytes were used at a leukocyte-to- 
RK cell ratio of 10 (3 X  106 leukocytes/3 X  105 RK cells). At the end of 48 h the leukocytes 
and medium were aspirated and the monolayers were washed three times with PBS. The RK 
cells then were removed by scraping, resuspended in  1 ml of GM, frozen and thawed three 
times, and the titer of intracellular virus was determined (7). Titrations were done in triplicate, 
the data were averaged and expressed as PFU (log 10)  per well.  Most experiments were re- 
peated three or more times. 
Preparation  of Supernatant  Fluids from Sensitized Leukocytes.--Monolayers  of uninfected 
RK cells were incubated with sensitized leukocytes obtained from animals immunized with 
either CFA or HSV. PPD or UV-inactivated HSV then was added and supernatant fluids were 
harvested at  different times thereafter. In  these experiments, anti-HSV antibody was not 
included in the overlay media. Supernatant fluids were centrifuged at 1,500 g for 30 min and 
stored at -70°C. The fluids were reconstituted with an equal vol of GM and then incubated 
with fresh uninfected monolayers. At appropriate intervals thereafter, the fluids were aspirated, 
the monolayers washed three times and challenged with approximately 30 PFU of HSV. 24 h 
after infection the monolayers were washed, the ceils were removed and titrated for infectious 
virus (7). 
Interferon Assay.--1 ml of supernatant fluids from CFA- or HSV-sensitized leukocytes was 
diluted with an equal vol of GM and incubated overnight with fresh uninfected RK mono- 
layers. The supernatant fluids then were removed and the monolayers were challenged with 50 
PFU of VSV. Interferon titers were expressed as the reciprocal of the highest dilution of the 
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RESULTS 
Inhibition of HSV Replication  by Leukocytes from Animals Immunized with 
CFA.--Monolayers infected  with  HSV  were incubated  with  leukocytes from 
rabbits  that  had been immunized with  either  CFA  or IFA.  PPD  was added, 
and 48 h later the virus titer was determined. The data in Table I show that in 
the  absence  of  leukocytes,  PPD  did  not  inhibit  viral  replication.  Similarly, 
PPD  added to leukocytes from animals immunized with IFA failed to inhibit 
viral replication in excess of that produced by leukocytes alone (7).  However, 
when PPD  was added  to leukocytes from animals immunized with  CFA,  the 
virus titer was reduced from  10  4.2 to  10  2.8 PFU. 
Effect  of CFA-Sensitized  Leukocytes  on  Viral  Replication  at Different  Times 
after Infection.--To  determine how rapidly CFA-sensitized leukocytes exerted 
their  inhibitory  effect,  monolayers  that  had  been  infected  with  HSV  were 
incubated with  sensitized leukocytes plus  PPD,  and  at  different times there- 
after the virus titer was determined. The data in Table II show that within 24 h 
TABLE  I 
Inhibition  of HSV  Replication  by  Leukocytes from  Rabbits Immunized  with  Incomplete  or 
CFA * 
Leukocytes 
Treatment  Absent  Present 
IFA  CFA 
PFU, logto 
NoPPD  5.5  4.3  4.2 
PPD  5.5  4.3  2.8 
* Monolayers infected with approximately 30 PFU of HSV were incubated with 5 #g of 
PPD plus leukocytes at a leukocyte-to-RK-cell  ratio of 10. At the end of 48 h, the leukocytes 
were removed and the monolayers washed and titrated for virus. 
TABLE  lI 
Effect of CFA-Sensitized  Leukocytes on HSV Replication at Different  Times After Infection* 
Leukocytes 
H after  infection  Absent  Present 
No PPD  PPD  No PPD  PPD 
PFU, loglo 
24  3.9  4.0  3.3  2.8 
48  5.0  5.0  3.4  1.4 
72  5.3  5.1  2.5  0 
* Monolayers infected with approximately 30 PFU of HSV were incubated with 5 #g of 
PPD plus CFA-sensitized leukocytes at a leukocyte-to-RK-cell  ratio of 10. At times indicated, 
the leukocytes were removed and the monolayers were washed and titrated for virus. 768  CELLULAR  IMMUNITY  TO  HERPES  SIMPLEX  VIRUS 
after infection,  the virus titer in monolayers incubated with sensitized leuko- 
cytes plus PPD  was 102-s PFU as compared to  103"3 PFU in monolayers incu- 
bated with sensitized leukocytes but no PPD.  At 48 h  the virus titer was re- 
duced by 99 %; at 72 h no virus was detected. In contrast, monolayers that had 
been incubated  with  PPD,  but  without  leukocytes, contained  approximately 
10 ~-° PFU of HSV. 
In other experiments (data not shown), CFA-sensitized leukocytes plus PPD 
were added to monolayers 24 h  after initiation of the infection. 48 h  later, the 
virus titer was reduced by > 99 % as compared to that in monolayers incubated 
with a similar concentration of leukocytes but without PPD. 
Comparison  of  the  Inhibitory  Effect  of  CFA-Sensitized  Leukocytes from  the 
Peritoneal Cavity and Spleen.--Peritoneal  and splenic leukocytes were obtained 
from the same rabbit and incubated with HSV-infected monolayers at a leuko- 
cyte-to-RK-cell ratio of 10. The data in Table III show that in the absence of 
PPD,  splenic leukocytes did  not  inhibit  viral  replication,  whereas peritoneal 
leukocytes  produced  the  expected  inhibition  of  viral  replication  (7).  In  the 
presence of PPD, peritoneal leukocytes completely inhibited viral replication, 
whereas splenic leukocytes reduced the virus titer from 10  ~-7 to 103 -s. 
Effect  of  Different  Concentrations  of  CFA-Sensitized  Leukocytes  on  Viral 
Replication  and Plaque  Formation.--The  data  in  Table IV show  that  in  the 
absence of PPD, low concentrations of sensitized leukocytes did not inhibit viral 
replication. Only when the ratio of leukocytes to RK cells equalled or exceeded 
2.5 was viral replication inhibited. In the presence of PPD, however, there was 
far greater inhibition of viral replication. The degree of inhibition was depend- 
ent upon both the concentration of leukocytes and the concentration of PPD. 
At a  leukocyte-to-RK-cell ratio of 10,  PPD  inhibited viral replication by 3-4 
logs more  than  that  produced  by leukocytes  alone.  Maximal  inhibition  was 
produced by 10 #g of PPD. Even more important is the fact that PPD inhibited 
TABLE  III 
Inhibition  of HSV  Replication by  CFA-Sensitized Leukocytes from  Spleen and  Peritoneal 
Exudate* 
Leukocytes 
Concentration of PPD  Absent  Present 
Spleen  Peritoneal exudate 
Izg  PFU, loglo 
0  5.7  5.7  4.7 
10  5.8  4.3  0 
100  6.1  3.8  0 
* Monolayers infected with approximately 30 PFU of HSV were incubated with PPD plus 
leukocytes at a leukocyte-to-RK-cell ratio of 10. Peritoneal and splenic leukocytes were har- 
vested from the same CFA-sensitized rabbit. At the end of 48 h, the leukocytes were removed 
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TABLE IV 
Inhibition  of tISV  Replication by Different Concentrations of CFA-gensitized Leukocytes* 
Ratio of leukocytes to RK cells 
Concentration of PPD (~g) 
None  1  10  100 
PFU, Ioglo 
Nole~ytes  6.2  6.3  6.2  6.3 
0.1  6.3  6.1  5.0  4.8 
0.25  6.3  5.4  4.2  4.6 
0.5  6.0  5.2  4.2  4.0 
1.0  6.2  4.8  3.2  3.5 
2.5  5.7  3.0  3.2  3.2 
5.0  4.7  2.9  2.0  2.2 
10.0  4.2  0.9  0.3  0.9 
* Monolayers infected with approximately 30 PFU of HSV were incubated with different 
concentrations of CFA-sensitized leukocytes  and PPD. At the end of 48 h the leukocytes  were 
removed and the monolayers  were washed and titrated for virus. 
viral replication by over 90% when the ratio of CFA-sensitized leukocytes to 
RK cells was as low as 0.1. 
To show that the inhibition of viral replication by leukocytes in the absence 
of PPD was not due to an in vitro allograph reaction, RK cells and peritoneal 
leukocytes were obtained from the same rabbit.  In each of three separate ex- 
periments (data not shown), HSV replication was inhibited to about the same 
degree as noted in column 2 of Table IV. 
The effect of different concentrations of CFA-sensitized leukocytes on the 
formation of plaques is illustrated in Table V. In the absence of PPD, low con- 
centrations of leukocytes did not inhibit plaque formation. Only when the ratio 
of leukocytes to RK cells was 2.5 or greater was plaque formation inhibited by 
50%. In the presence of PPD, plaque formation was markedly inhibited by a 
leukocyte-to-RK cell ratio of 0.5. In general, the plaques that did develop after 
exposure to PPD-stimulated leukocytes were considerably smaller  than  those 
that appeared after exposure to unstimulated leukocytes. 
Inhibition  of HSV  Replication  by Supernatant  Fluids from  CFA-Sensitized 
Leukocyte~.--Previously  we  found  that  high  concentrations  of  unsensitized 
leukocytes were toxic to monolayers (7),  and that this toxicity was at least in 
part responsible for preventing the cell-to-cell  spread of HSV infections.  The 
data in Tables IV and V of the present report show that low concentrations of 
PPD-stimulated leukocytes (ratio  <  0.5)  also can inhibit the spread of HSV. 
Microscopic examination of monolayers exposed to low concentrations of stimu- 
lated  leukocytes showed  that  stimulated  leukocytes adhered  more firmly  to 
monolayers than unstimulated leukocytes but  revealed little,  if any, evidence 
of cytotoxicity. Studies measuring  the release  of  5~Cr from monolayers treated 
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TABLE  V 
Inhibition of Plaque Formation by Different Concentrations of CFA-Sensitized Leukocytes* 
Ratio of leukocytes to RK cells 
PPD 
Absent  Present 
No. of plaques 
No leukocytes  29  27 
0.10  23  23 
0.25  23  17 
0.50  21  5 
1.0  17  4 
2.5  9  0 
5.0  6  0 
10.0  3  0 
* Monolayers infected with approximately 30 PFU of HSV were incubated with different 
concentrations of CFA-sensitized leukocytes, plus 100/zg of PPD. At the end of 48 h  the leu- 
kocytes were removed, the monolayers were washed, and the number of plaques counted. 
evidence for cell damage (data not shown). The fact that  low concentrations of 
CFA-sensitized leukocytes exposed to PPD  inhibited viral replication  without 
producing cytotoxicity, while high  concentrations  of  unstimulated  leukocytes 
inhibited viral replication  as a  result of cytotoxicity, suggested  that  different 
mechanisms were involved in these two situations.  For this reason we began to 
suspect that an immunologically induced mediator was being produced by the 
PPD-stimulated leukocytes. 
To test this possibility, CFA-sensitized leukocytes plus PPD were incubated 
with uninfected RK cells for 24 h. Supernatant fluids were harvested from these 
cultures  and  mixed with  an equal  vol of GM. The reconstituted  supernatant 
fluids were incubated with fresh uninfected  monolayers for 3,  12,  24,  or 48 h. 
The  monolayers  then  were  washed  and  challenged  with  HSV.  The  data  in 
Table  VI  show  that  supernatant  fluids  markedly  inhibited  viral  replication 
when added to monolayers for 12 or more h  before challenge with HSV. Viral 
replication  was not  substantially inhibited  if the monolayers were exposed to 
the  supernatant  fluids for only 3  h  before challenge.  Supernatant  fluids from 
CFA-sensitized  leukocyte cultures  that  had  not  been  exposed  to  PPD  failed 
to protect the monolayers against HSV. Supernatant fluids of leukocytes from 
animals injected with IFA and incubated with PPD  also failed to inhibit viral 
replication  (data not shown). 
Comparison of the viral inhibitory activity of supernatant  fluids from CFA- 
sensitized peritoneal leukocyte cultures with  CFA-sensitized  splenic leukocyte 
cultures revealed marked inhibitory activity in the former within 2 h  after ex- 
posure to  PPD  while relatively little  activity was found  in  the latter despite 
exposure to PPD for as long as 24 h  (data not shown). 
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TABLE  VI 
Inhibition of HS V Replication by Supernatant Fluids  from CFA-Sensitized  Leukocytes Incubated 
with PPD* 
Concentration of PPD used to 
prepare supernatant  fluids 
Time (h) that monolayers were exposed to supernatant fluids 
before challenge with HSV 
3  12  24  48 
#g  PFU, loglo 
GMcontrol~  4.8  3.9  4.5  3.9 
0  4.8  4.0  4.1  3.7 
10  4.4  1.5  1.0  1.0 
1~  4.4  0  0  0 
*CFA-sensitized leukocytes plus PPD were incubated for 24 h with uninfected RK cells at 
a leukocyte-to-RK-cell ratio of 10. The supernatant fluids were removed and diluted with an 
equal vol of GM. Uninfected monolayers then were exposed to either  the reconstituted  super- 
natant fluids or fresh GM.  At various  times thereafter,  the monolayers  were washed and 
challenged with approximately  30 PFU of HSV. 24 h after  challenge the monolayers were 
washed and the cells titrated for virus. 
:~ Fresh GM (no leukocytes or PPD). 
natant  Fluid.--Different  concentrations  of  CFA-sensitized  leukocytes  plus 
PPD were incubated with uninfected RK cells. 24 h later the supernatant fluids 
were harvested  and reconstituted  with  an equal  vol of GM.  Fresh  uninfected 
RK monolayers were incubated  with  the  reconstituted  supernatant  fluids for 
24 h, washed, and then challenged with HSV. The data in Table VII show that 
supernatant fluids obtained from RK cultures exposed to leukocytes at a  ratio 
of 0.005 reduced the virus titer from 10  s'6 to 102-4. Thus, under the conditions 
of our system,  approximately  1,500 leukocytes or less than one leukocyte per 
200 RK cells inhibited HSV replication by over 90 %. 
Properties of Inhibitor in Supernatant Fluid.--The inhibitor  was nondialyz- 
able, did not sediment at 100,000 g for 1 h, was relatively resistant to treatment 
at pH 2.0 for 24 h at 4°C (titer reduced from 1 : 256 to 1 : 128), lost some activity 
when heated  at 56°C for 1 h  (titer  reduced from 1:256 to 1:64),  and was in- 
activated by exposure to trypsin (1.25 mg/ml) for 5 h at 37°C. The inhibitor did 
not neutralize HSV, it was species specific in that it did not inhibit replication 
of VSV or HSV in mouse L cells, but it was not virus specific in that it inhibited 
HSV and VSV in RK cells. From these studies we conclude that the inhibitor 
is interferon. When compared with a rabbit interferon standard obtained from 
the  National  Institute  of  Allergy  and  Infectious  Diseases,  the  supernatant 
fluid prepared from 3 X  l0  s CFA-sensitized leukocytes that had been incubated 
with  100 #g of PPD  for 24 h, contained at least  256 U  of interferon/ml. 
Inhibition  of ItSV Replication by HSV-Sensitized  Leukocytes.--The  experi- 
ments described  above showed that  CFA-sensitized leukocytes stimulated  by 
an antigen  (PPD) unrelated to HSV could inhibit HSV  replication.  The next 
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TABLE VII 
Inhibition of HSV Replication by Supernatant Fluids Produced  with Different Concentrations of 
CFA-Sensitized Leukocytes* 
Ratio of leukocytes to RK cells  used to prepare  Virus titer 
supernatant  fluids 
PFU, logio 
PPD control~  3.9 
GM control§  3.6 
0.005  2.4 
0.01  2.5 
0.025  2.3 
O.05  1.7 
0. l  0 
O.25  0 
* Different concentrations  of CFA-sensitized  leukocytes  plus 100/zg  of PPD were incubated 
for 24 h with uninfected RK cells. The supernatant fluids were removed, diluted with an equal 
vol of GM, and incubated with uninfected RK monolayers for 24 h. The monolayers  then were 
washed, challenged with approximately 30 PFU of HSV, and 24 h later titrated for virus. 
J; No leukocytes. 
§ Fresh GM (no leukocytes  or PPD). 
also could inhibit HSV replication.  Peritoneal and splenic leukocytes obtained 
from HSV-immunized rabbits were added to monolayers infected with approxi- 
mately 30 PFU of HSV; UV-inactivated viral  antigen (1.0  X  106 to 1.0 X  108 
PFU)  then  was  added  to  stimulate  the  sensitized  leukocytes.  The  data  in 
Table VIII show that in the absence of UV-inactivated virus, peritoneal leuko- 
cytes produced  the  usual  reduction  in  virus  titer.  However,  when  UV-inac- 
tivated  virus  was  added,  HSV  replication  was  inhibited  to  a  much  greater 
extent  (e.g.,  at  a  peritoneal  leukocyte-to-RK-cell ratio  of  10,  the  virus  titer 
was reduced by over 99.9% from 105.9 to 102.7 PFU). In the absence of leuko- 
cytes, UV-inactivated virus added to RK cells did not inhibit HSV replication. 
In general,  UV-inactivated virus incubated with  unsensitized leukocytes pro- 
duced relatively little  inhibition of viral  replication,  although in some experi- 
ments between 30% and 90% inhibition was observed (data not shown). As in 
the case of CFA-sensitized leukocytes, the degree of viral inhibition produced 
by HSV-sensitized leukocytes was greater with peritoneal than with the splenic 
leukocytes and was dependent upon both the concentration of leukocytes and 
the concentration of antigens. 
Inhibition  of HSV  Replication  by Supernatant  Fluids from  HSV-Sensitized 
Leukocytes.--The  data in Table IX show that supernantant  fluid  from HSV- 
sensitized leukocytes that had been exposed to UV-inactivated virus completely 
inhibited HSV replication. In contrast, supernatant fluid from HSV-sensitized 
leukocytes that had not been exposed to UV-inactivated virus produced sub- 
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TABLE  VIII 
Inhibition  of HSV Replication by HSV-Sensitized  Leukocytes* 
Ratio of leukocytes  to RK cells§ 
UV-inactivated HSV~:  Splenic  Peritoneal 
None 
5:1  10:1  5:1  10:1 
PFU, logto 
None  7.9  7.6  7.4  6.4  5.9 
1  ×  106  8.0  7.5  7.2  6.4  4.8 
1  X  l0 s  7.7  6.9  6.0  3.7  2.7 
* Monolayers infected with approximately 30 PFU  of HSV were  incubated with HSV- 
sensitized splenic or  peritoneal leukocytes plus different concentrations of  UV-inactivated 
HSV. Anti-HSV antibody was not included in the overlay media. At the end of 48 h the mono- 
layers were washed and titrated for infectious virus. 
~: Number of PFU before UV-inacfivation. 
§ Leukocytes were harvested 9 days after intravenous immunization with 3 X  10 s PFU of 
infectious HSV. 
TABLE  IX 
Inhibition  of HSV Replication by Supernatant  Fluids from HS V-Sensitized Leukocytes* 
Preparation of supernatant fluid 
Time that monolayers  were exposed 
to supernatant fluids before  challenge 
with HSV 
HSV-sensitized 
leukocytes$  Treatmen:  24 h  48 h 
PFU, loglo 
Absent  None§  4.6  4.6 
Present  None§  3.7  3.5 
Present  UV-inacfivated HSV  0  0 
* HSV-sensitized leukocytes, at a  leukocyte-to-RK-cell ratio of  10, were incubated with 
1 X  l0 s PFU of UV-inactivated HSV. Anti-HSV antibody was not included in the overlay 
media. 24 h later, the supernatant fluids were removed and reconstituted with an equal vol of 
fresh GM. The reconstituted supernatant fluids were then incubated with fresh uninfected RK 
monolayers for 24 or 48 h  before challenge with approximately  30 PFU of HSV. 24 h  after 
challenge, the monolayers were washed and titrated for virus. 
:~ Leukocytes were harvested 12 days after intravenous immunization with 3 X  10 s PFU of 
infectious HSV. 
§ Fresh GM. 
showed  that  it had  the  same  properties  as  the interferon produced  by  PPD- 
stimulated leukocytes. 
DISCUSSION 
Previously  we  showed  that  high  concentrations  of  unsensitized  leukocytes 
could  inhibit HSV  replication  and  the development  of  viral plaques  (7).  The 
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inhibiting viral replication and plaque formation.  The mechanisms by which 
unsensitized and sensitized leukocytes inhibit viral  replication  appear  to  be 
quite different. Unsensitized leukocytes (at high concentrations) acted by exert- 
ing a generalized cytotoxic effect.  PPD-stimulated leukocytes (at  low concen- 
trations) were not cytotoxic but inhibited viral replication by producing inter- 
feron. In both situations, the inhibition was nonspecific (i.e.,  an HSV antigen 
recognition phase was not required).  In  the case of leukocytes sensitized to 
HSV, a specific  HSV antigen recognition was required, but only to stimulate 
the leukocytes; the effector phase  (i.e.,  interferon production) was again non- 
specific. 
Our studies also  indicate that the mechanism of action of  immunologically 
stimulated leukocytes (i.e.,  interferon production)  is not only different from 
that  of unsensitized leukocytes (i.e.,  cytotoxicity), but  that  the number  of 
leukocytes required to inhibit viral replication is markedly different in the two 
situations. To inhibit viral replication with unsensitized leukocytes, a relatively 
high ratio of leukocytes to RK cells (> 2.5:1) was required. In contrast, viral 
replication was inhibited by immunologically stimulated leukocytes at a ratio 
of leukocytes to RK cells of less than 0.1. When supernatant fluids from cultures 
of stimulated leukocytes were used, less than one leukocyte per 200 RK cells 
was capable of inhibiting viral replication by over 90 %. This is considerably 
less cells than the number of immune leukocytes generally required to destroy 
specific  target cells (10), and suggests that a relatively small number of leuko- 
cytes at the site of the lesion may be capable of stopping viral spread by re- 
ducing the susceptibility of the surrounding tissue. 
Experiments from other laboratories also  have shown that leukocytes from 
animals immune to a specific antigen (viral or nonviral) produced more  inter- 
feron when exposed to that antigen than leukocytes from nonimmune animals 
(11-19).  Recently, Youngner and Salvin  (17)  reported that immunologically 
induced interferon differs in its physical properties from  nonimmunologically 
induced interferon; at pH  2.0 the interferon was inactivated. In our studies, 
however, the immunologically induced interferon was stable at pH 2.0.  It is 
quite possible that different types and amounts of interferon may be produced 
by different subpopulations of leukocytes (21-23).  This might be one of the 
explanations for the lower amount of interferon produced in our experiments 
by splenic as compared to peritoneal leukocytes. The specific cell type(s) pro- 
ducing interferon in our system also  remains to be determined, but evidence 
from other laboratories indicates that both immune lymphocytes and macro- 
phages can produce interferon (12, 15, 18). 
Endotoxin is a common contaminant of biological  materials and can lead to 
the release of interferon from leukocytes (24).  The demonstration that PPD 
did not release interferon following incubation with either unsensitized or IFA- 
sensitized leukocytes argues against endotoxin contamination as a major factor 
in our experiments.  Supernatant fluids from unsensitized leukocytes (7)  and DONALD  L.  LODMELL  AND  ABNER  LOUIS  NOTKINS  775 
CFA-sensitized leukocytes that had not been exposed to PPD  also  contained 
little, if any, interferon (Table VI). In contrast, supernatant fluids from HSV- 
sensitized leukocytes that had not been exposed to UV-inactivated virus con- 
tained some interferon (Table IX). Why supernatant fluids from unstimulated 
HSV-sensitized,  but  not  unstimulated  CFA-sensitized  leukocytes contained 
interferon is not clear, but the explanation may lie in the fact that the CFA- 
sensitized leukocytes were harvested 3-6 months after immunization, whereas 
HSV-sensitized leukocytes were harvested 9-12 days after immunization. Con- 
ceivably HSV-sensitized leukocytes were still in an "activated" state from in 
vivo exposure to the live virus. Whether HSV-sensitized leukocytes obtained 
weeks or months after immunization also  "spontaneously" release interferon 
has not yet been determined. 
Another issue that remains to be resolved is whether immunologically  induced 
interferon is really needed to stop the spread of HSV, since most of the non- 
inflammatory cells in which HSV replicates (e.g., RK cells) are potentially cap- 
able of producing interferon. It is known, however, that certain viruses are poor 
inducers of interferon (20, 25).  In our experiments little if any interferon was 
found in the supernatant fluids of RK cells exposed to either infectious or UV- 
inactivated virus (data not shown). In contrast, interferon was detected within 
several  hours  after  stimulation  of  sensitized leukocytes. This  suggests  that 
interferon produced by leukocytes at the site of infection may be needed by the 
host to cope with viruses that otherwise are poor inducers of interferon. More- 
over, immune leukocytes, in contrast to other target cells (e.g., fibroblast), can 
make interferon when exposed to antigens that do not contain nucleic acid (e.g., 
PPD). Theoretically, at least, this would enable the immune host to produce 
interferon in response to  a  variety of viral components (e.g.,  structural  and 
nonstructural proteins)  to which the nonimmune host would not react.  Thus, 
cellular immunity may amplify the host's interferon-producing capacity. 
In conclusion, the present study with CFA- and HSV-sensitized  leukocytes 
supports and expands the concept that the host's immunological defense against 
HSV consists of two phases:  an immunologically specific  antigen recognition 
phase and a nonspecific effector phase (7)  (Fig. 1). In the first phase, antiviral 
antibody,  complement and immune leukocytes react with virus or  virus-in- 
fected cells.  This  generates  a  variety of  mediators  (e.g.,  C5a,  lymphocyte- 
derived chemotactic factor, migration inhibitory factor) which can attract and 
keep inflammatory cells  at  the site of the infection (26,  27).  In  addition,  a 
number of other mediators including lymphotoxin and interferon are generated. 
The nonspecific phase of the defense consists of the action of these inflammatory 
cells  and mediators on both  infected and  adjacent uninfected cells,  thereby 
breaking cell-to-cell  contact and inhibiting viral replication. Because the virus 
spreads so rapidly from cell-to-contiguous cells, the specific phase of the defense 
which destroys virus-infected cells appears to have little effect on halting the 
infection (7). It appears that it is the nonspecific phase of the defense, that is, 776  CELLULAR IMMUNITY TO HERPES SIMPLEX VIRUS 
FIG. 1.  Sites  of action of the specific  and nonspecific  immune responses to HSV infection. 
the nonspecific cytotoxicity produced by inflammatory cells and lymphotoxin 
and  the inhibition  of viral  replication produced by immunologically-induced 
interferon, which is required to finally stop the cell-to-cell spread of HSV. 
SUMMARY 
Rabbit kidney cell monolayers infected with herpes simplex virus (HSV) were 
incubated  with  leukocytes from  rabbits  immunized  with  complete  Freund's 
adjuvant.  When  the  leukocytes were  exposed  to  tuberculin  purified protein 
derivative (PPD),  viral replication and plaque formation were markedly  in- 
hibited.  Similarly, when leukocytes from animals immunized with HSV were 
exposed  to  UV-inactivated  HSV,  viral  replication  was  markedly  inhibited. 
Exposure of leukocytes from unimmunized animals or animals immunized with 
incomplete Freund's adjuvant to UV-inactivated virus or PPD produced rela- 
tively little inhibition of viral  replication.  Examination of supernatant  fluids 
from stimulated cultures revealed a soluble mediator that had the properties of 
interferon. Interferon production was detected within several hours after expo- 
sure of sensitized leukocytes to antigen. Supernatant fluids from as few as one 
sensitized leukocyte per 200  rabbit kidney cells inhibited HSV replication by 
over 90%. These findings support the concept that the cellular immune response 
to HSV consists of two phases: an immunologically specific antigen recognition 
phase,  and  a  nonspecific effector phase  that stops HSV spread by generating 
interferon. 
The authors gratefully acknowledge  the invaluable technical assistance of Larry Ewalt. 
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